Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. provides physician services for women, babies and children across hospital settings and office-based practices. Its recurring updates center on obstetrics, maternal-fetal medicine, neonatology, neonatal intensive care unit activity and other pediatric subspecialties, with revenue concentrated in neonatology and pediatric subspecialty care.
Company news also covers quarterly operating results, same-unit revenue trends, reimbursement and payor-mix factors, patient acuity, hospital contract administrative fees, practice acquisitions and dispositions, service expansions, clinical quality initiatives and neonatology education through NEO: The Conference for Neonatology.
Pediatrix Medical Group (NYSE: MD) will host an investor conference call on August 4, 2022, at 9:00 a.m. ET, to discuss its Q2 2022 operational results. A detailed press release will precede the call, issued before market opening on the same day. Pediatrix is a leading provider of physician services, focusing on women, babies, and children through over 4,800 affiliated clinicians across 37 states and Puerto Rico.
For further information, visit www.pediatrix.com/investors.
Mednax, Inc. (NYSE: MD) has announced its corporate name change to Pediatrix Medical Group, Inc., effective July 1, 2022. This rebranding emphasizes its commitment as a premier provider of healthcare services for women, infants, and children. CEO Mark S. Ordan highlighted the significance of returning to the well-respected Pediatrix name. Shareholders are not required to take any action as existing shares will automatically represent the new name. This transition marks a strategic focus on pediatrics and obstetrics, following the company's extensive service history since its inception in 1979.
Mednax, Inc. announces the appointment of James D. Swift, M.D. as Chief Operating Officer and Curtis B. Pickert, M.D. as Chief Physician Executive, emphasizing their commitment to high-quality patient care and operational growth. Both doctors have over a decade of leadership experience within the company. Dr. Swift, previously Executive Vice President and Chief Development Officer, and Dr. Pickert, former Executive Vice President of Clinical Services, aim to enhance Mednax's service delivery across various specialties.
Mednax, Inc. (NYSE: MD) reported a loss from continuing operations of $0.25 per share for Q1 2022, driven by a $57 million pretax loss on debt extinguishment. Net revenue reached $482 million, marking an increase from $446.8 million in Q1 2021. Adjusted EPS improved to $0.33, up from $0.24 in the prior year. The company experienced growth in patient volume, with same-unit revenue rising by 1.3%. However, operational challenges persisted, with a notable decrease in investment income and increased expenses related to practice salaries and benefits.
Mednax, Inc. (NYSE: MD) announced an investor conference call scheduled for April 28, 2022, at 9:00 a.m. ET. The call will discuss operational results for the quarter ending March 31, 2022. A detailed press release will be issued that morning prior to market opening. Mednax is a national medical group providing specialized physician services focused on women, babies, and children through its Pediatrix brand. The company emphasizes coordinated care across various specialties and has a network of over 4,700 clinicians in 38 states and Puerto Rico.
Mednax, Inc. (NYSE: MD) has announced a brand evolution, adopting the Pediatrix® Medical Group brand nationwide. This change reflects their commitment to providing specialized healthcare for women, babies, and children. The company’s unified branding aims to enhance awareness of its extensive services across 40 years of operations.
Pediatrix-affiliated clinicians care for one in four newborns in the U.S., supported by over $25 million in investments for quality improvements. The new logo symbolizes their commitment to coordinated care within obstetrics, maternal-fetal medicine, and pediatric services.
Mednax, Inc. (NYSE: MD) will host two major neonatal medicine conferences in San Diego from March 1-6. The events, Specialty Review in Neonatology and NEO: The Conference for Neonatology, aim to enhance care for premature and critically ill newborns, bringing together around 750 healthcare professionals. Specialty Review focuses on board certification preparation, while NEO provides updates on neonatal management. The conferences feature renowned speakers and offer continuing education credits, emphasizing the commitment to improving clinical outcomes.
Mednax, Inc. (NYSE: MD) will present at J.P. Morgan’s 2022 Global High Yield and Leveraged Finance Conference on February 28, 2022, at 10:00 a.m. ET in Miami. The event will be accessible through live audio webcasts. Mednax is known for providing physician services under the Pediatrix brand, specializing in pediatric and maternal-fetal care with over 4,700 affiliated clinicians across 38 states and Puerto Rico. Founded in 1979, the company emphasizes high-quality, evidence-based care, supported by a strong commitment to research and education.
Mednax, Inc. (NYSE: MD) is set to present at SVB Leerink’s 11th Annual Global Healthcare Conference on February 18, 2022, at 8:40 a.m. ET. This virtual event will feature a live audio webcast for investors. Mednax is a national medical group focused on providing high-quality physician services through its Pediatrix brand, offering care in specialties such as obstetrics and neonatology. The company has over 4,700 affiliated clinicians across 38 states and Puerto Rico, emphasizing coordinated, compassionate medical care.
Mednax, Inc. (NYSE: MD) reported Q4 2021 earnings of $0.47 per share, with an Adjusted EPS of $0.52. The company achieved net revenue of $499 million, up from $416.6 million YoY, while income from continuing operations rose to $68 million. Adjusted EBITDA for the quarter was $81 million, benefiting from $18.4 million in provider relief funds. For 2021, total revenue reached $1.91 billion, with net income of $108 million, or $1.26 per share. Mednax anticipates at least $270 million in Adjusted EBITDA for 2022, excluding further relief fund contributions.